European Journal of Clinical Pharmacology

, Volume 74, Issue 8, pp 1093–1094 | Cite as

Therapeutic drug monitoring of vancomycin in a patient on extracorporeal membrane oxygenation therapy in intensive care unit

  • L. Herrera HidalgoEmail author
  • A. B. Guisado Gil
  • M. V. Gil Navarro
  • L. Martín Villén
  • Y. Corcia Palomo
  • R. Martín Bermúdez
Letter to the Editor

To the editor,

Critically ill patients exhibit extreme alterations in drug pharmacokinetics (PK) due to several pathophysiological changes. These variations may alter PK parameters as apparent volume of distribution (Vd), total clearance (Cl), and protein binding, complicating achieving adequate drug concentrations [1]. Extracorporeal membrane oxygenation (ECMO) increases the physiological derangements, leading to deeper PK changes and more variability. Data available is limited, but suggests that ECMO can alter PK by increasing the Vd, modifying drug elimination, and drug sequestration in the ECMO circuit. In addition, ECMO therapy may be accompanied by a systemic inflammatory response syndrome (SIRS) and hemodilution [2, 3]. Therapeutic drug monitoring (TDM) and dose individualization is recommended to prevent sub-optimal drug exposure and minimize the risk of side effects. We describe the PK characteristics, TDM result, and dose individualization in a young adult man with clinical...


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Blot SI, Pea F, Lipman J (2014) The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77:3–11CrossRefPubMedGoogle Scholar
  2. 2.
    Shekar K, Fraser JF, Smith MT, Roberts JA (2012) Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 27(6):741–7e9CrossRefPubMedGoogle Scholar
  3. 3.
    Ha MA, Sieg AC (2017) Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37(2):221–235CrossRefGoogle Scholar
  4. 4.
    de Gatta MDMF, Revilla N, Calvo MV, Domínguez-Gil A, Navarro AS (2007) Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 33(2):279–285CrossRefGoogle Scholar
  5. 5.
    Donadello K, Roberts JA, Cristallini S, Beumier M, Shekar K, Jacobs F, Belhaj A, Vincent JL, de Backer D, Taccone FS (2014) Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care 18(6):632CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cristallini S, Hites M, Kabtouri H, Roberts JA, Beumier M, Cotton F, Lipman J, Jacobs F, Vincent JL, Creteur J, Taccone FS (2016) New regimen for continuous infusion of vancomycin in critically ill patients. Antimicrob Agents Chemother 60(8):4750–4756CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wu CC, Shen LJ, Hsu LF, Ko WJ, Wu FLL (2016) Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation. J Formos Med Assoc 115(7):560–570CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PharmacyUniversity Hospital Virgen del Rocío/Institute of Biomedicine of Seville (IBiS)SevilleSpain
  2. 2.Department of Intensive CareUniversity Hospital Virgen del RocioSevilleSpain

Personalised recommendations